Doctors use ejection fraction percentages to categorize left-sided heart failure. According to a 2022 article, people with HFpEF have an ejection fraction of more than 50%.

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

It has specific treatments depending on the type of amyloidosis, in addition to the treatments mentioned above for heart failure. Dear Dr. Roach: I am just getting over the horrible shingles.

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380 (9851):1387-1395. doi ...

Overall, SGLT2 inhibitors show clear benefits in both heart failure with reduced ejection fraction (HFrEF) and HFpEF populations, while sacubitril-valsartan is emerging as an important HFpEF therapy.

Solomon, S. D., et al. (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. doi.org/10.1056/NEJMoa2407107.

New FDA Indication: Kerendia (finerenone) is now approved to reduce cardiovascular death, heart failure (HF) hospitalization, and urgent HF visits in adults with HF and left ventricular ejection ...

Given the current trends, heart failure with normal ejection fraction will become the most common form of heart failure, for which we do not currently have an evidence-based successful treatment.

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a study published online Sept ...